24/7 Wall St.
05-06-2008, 02:50 PM
24/7 Wall St. Daily News
Here are some of the top stories today that affecting key drug and biotech stocks: GlaxoSmithKline (NYSE: GSK) reorganized its corporate structure, increasing focus on emerging markets such as China, Russia, Brazil, India and the Middle East. New CEO Andrew Witty, who will take over on May 22, approves the moves. Shares are down $0.25 to $44.64 in mid-day trading. The 52-week range is $40.51 to $58.23. Merck (NYSE: MRK) down slightly despite news Monday that they are to cut 1,200 sales jobs to cut costs. Yesterday, shares dropped $0.47. Shares are down $0.13 to $38.85 in mid-day trading on... http://feeds.feedburner.com/~f/typepad/RyNm?i=sPoZDH</img> (http://feeds.feedburner.com/~f/typepad/RyNm?a=sPoZDH) http://feeds.feedburner.com/~f/typepad/RyNm?i=cUtHGH</img> (http://feeds.feedburner.com/~f/typepad/RyNm?a=cUtHGH) http://feeds.feedburner.com/~f/typepad/RyNm?i=CNb7Kh</img> (http://feeds.feedburner.com/~f/typepad/RyNm?a=CNb7Kh)
complete story here... (http://www.247wallst.com/2008/05/biotech-busin-2.html)
Here are some of the top stories today that affecting key drug and biotech stocks: GlaxoSmithKline (NYSE: GSK) reorganized its corporate structure, increasing focus on emerging markets such as China, Russia, Brazil, India and the Middle East. New CEO Andrew Witty, who will take over on May 22, approves the moves. Shares are down $0.25 to $44.64 in mid-day trading. The 52-week range is $40.51 to $58.23. Merck (NYSE: MRK) down slightly despite news Monday that they are to cut 1,200 sales jobs to cut costs. Yesterday, shares dropped $0.47. Shares are down $0.13 to $38.85 in mid-day trading on... http://feeds.feedburner.com/~f/typepad/RyNm?i=sPoZDH</img> (http://feeds.feedburner.com/~f/typepad/RyNm?a=sPoZDH) http://feeds.feedburner.com/~f/typepad/RyNm?i=cUtHGH</img> (http://feeds.feedburner.com/~f/typepad/RyNm?a=cUtHGH) http://feeds.feedburner.com/~f/typepad/RyNm?i=CNb7Kh</img> (http://feeds.feedburner.com/~f/typepad/RyNm?a=CNb7Kh)
complete story here... (http://www.247wallst.com/2008/05/biotech-busin-2.html)